Full text is available at the source.
Abstract
Adding the mRNA-based vaccine intismeran autogene to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma patients.
- The trial was a phase III study named INTerpath-0001.
- The combination treatment was administered following surgery for melanoma.
- Results indicate a significant reduction in the risk of melanoma recurrence or mortality.
Simplified